Q Biomed buys SR89 generic and vows to lower prices

8 September 2016
drugs_pills_tablets_big

USA-based Q BioMed (OTCMKTS: QBIO) has bought the worldwide rights to the US Food and Drug Administration-approved drug strontium chloride (SR89) with the promise to keep prices down.

Q BioMed did the deal with fellow US firm Bio-Nucleonics, which it expects to pay $850,000 in cash and an aggregate of 110,000 shares of common stock.

SR89 provides long-lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases and has been proven to provide a long-term effect resulting in non-narcotic cancer pain relief and enhanced quality of life.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics